 Connection
Larry Moreland to Infliximab
This is a "connection" page, showing publications Larry Moreland has written about Infliximab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.693 |
|
|
|
-
Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022 06; 64:102234.
Score: 0.177
-
Moreland L. Infliximab in rheumatoid arthritis. Curr Rheumatol Rep. 2004 Oct; 6(5):334-5.
Score: 0.052
-
Mikuls TR, Moreland LW. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf. 2003; 26(1):23-32.
Score: 0.046
-
Misischia RJ, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin Investig Drugs. 2002 Jul; 11(7):927-35.
Score: 0.045
-
Daniel CL, Moreland LW. Infliximab: additional safety data from an open label study. J Rheumatol. 2002 Apr; 29(4):647-9.
Score: 0.044
-
Moreland LW. Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis. Isr Med Assoc J. 2001 Sep; 3(9):686-90.
Score: 0.042
-
Moreland LW, Russell AS, Paulus HE. Management of rheumatoid arthritis: the historical context. J Rheumatol. 2001 Jun; 28(6):1431-52.
Score: 0.041
-
Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother. 2001 Jan; 2(1):75-84.
Score: 0.040
-
Hughes LB, Moreland LW. New therapeutic approaches to the management of rheumatoid arthritis. BioDrugs. 2001; 15(6):379-93.
Score: 0.040
-
Moreland LW. Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun; 66(6):367-74.
Score: 0.036
-
Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999 May; 57:7-15.
Score: 0.036
-
Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999; 48(3):1-4.
Score: 0.035
-
Bradford RD, Pettit AC, Wright PW, Mulligan MJ, Moreland LW, McLain DA, Gnann JW, Bloch KC. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis. 2009 Sep 15; 49(6):924-7.
Score: 0.018
-
Shatin D, Rawson NS, Curtis JR, Braun MM, Martin CK, Moreland LW, Becker AF, Patkar NM, Allison JJ, Saag KG. Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. Pharmacoepidemiol Drug Saf. 2006 Jan; 15(1):11-8.
Score: 0.014
-
Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med Res Opin. 2005 Aug; 21(8):1181-90.
Score: 0.014
-
Shanahan JC, Moreland LW, Carter RH. Upcoming biologic agents for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2003 May; 15(3):226-36.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|